Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Homo sapiens

PROVIDER: GSE146625 | GEO | 2020/12/28

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

BRD9 Is a Critical Regulator of Androgen Receptor Signaling and Prostate Cancer Progression.

Project description:Switch/sucrose-nonfermentable (SWI/SNF) chromatin-remodeling complexes are critical regulators of chromatin dynamics during transcription, DNA replication, and DNA repair. A recently identified SWI/SNF subcomplex termed GLTSCR1/1L-BAF (GBAF; or "noncanonical BAF", ncBAF) uniquely contains bromodomain-containing protein BRD9 and glioma tumor suppressor candidate region 1 (GLTSCR1) or its paralog GLTSCR1-like (GLTSCR1L). Recent studies have identified a unique dependency on GBAF (ncBAF) complexes in synovial sarcoma and malignant rhabdoid tumors, both of which possess aberrations in canonical BAF (cBAF) and Polybromo-BAF (PBAF) complexes. Dependencies on GBAF in malignancies without SWI/SNF aberrations, however, are less defined. Here, we show that GBAF, particularly its BRD9 subunit, is required for the viability of prostate cancer cell lines in vitro and for optimal xenograft tumor growth in vivo. BRD9 interacts with androgen receptor (AR) and CCCTC-binding factor (CTCF), and modulates AR-dependent gene expression. The GBAF complex exhibits overlapping genome localization and transcriptional targets as bromodomain and extraterminal domain-containing (BET) proteins, which are established AR coregulators. Our results demonstrate that GBAF is critical for coordinating SWI/SNF-BET cooperation and uncover a new druggable target for AR-positive prostate cancers, including those resistant to androgen deprivation or antiandrogen therapies. SIGNIFICANCE: Advanced prostate cancers resistant to androgen receptor antagonists are still susceptible to nontoxic BRD9 inhibitors, making them a promising alternative for halting AR signaling in progressed disease.

| S-EPMC8026650 | biostudies-literature

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression - ChIP-Seq

Project description:BRD9 and BRD4 ChIP-Seq in LNCaP prostate cancer cells

2020-12-28 | GSE146623 | GEO

BRD9 is a critical regulator of androgen receptor signaling and prostate cancer progression - RNA-Seq

Project description:Standard RNA-Seq analysis from LNCaP cells treated with shBRD9 for 3d, shBRD9 for 11d, or 3 µM IBRD9 for 3d.

2020-12-28 | GSE146624 | GEO

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

Project description:BRD9 is a regulator of androgen receptor signaling and prostate cancer progression

| PRJNA611525 | ENA

CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.

Project description:Castration resistance is a major obstacle to hormonal therapy for prostate cancer patients. Although androgen independence of prostate cancer growth is a known contributing factor to endocrine resistance, the mechanism of androgen receptor deregulation in endocrine resistance is still poorly understood. Herein, the CAMK2N1 was shown to contribute to the human prostate cancer cell growth and survival through AR-dependent signaling. Reduced expression of CAMK2N1 was correlated to recurrence-free survival of prostate cancer patients with high levels of AR expression in their tumor. CAMK2N1 and AR signaling form an auto-regulatory negative feedback loop: CAMK2N1 expression was down-regulated by AR activation; while CAMK2N1 inhibited AR expression and transactivation through CAMKII and AKT pathways. Knockdown of CAMK2N1 in prostate cancer cells alleviated Casodex inhibition of cell growth, while re-expression of CAMK2N1 in castration-resistant cells sensitized the cells to Casodex treatment. Taken together, our findings suggest that CAMK2N1 plays a tumor suppressive role and serves as a crucial determinant of the resistance of prostate cancer to endocrine therapies.

| S-EPMC4279373 | biostudies-literature

An Integrated Network of Androgen Receptor and TMPRSS2-ERG Gene Fusion in Prostate Cancer Progression

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2010-05-18 | E-GEOD-14097 | biostudies-arrayexpress

Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth

Project description:This SuperSeries is composed of the SubSeries listed below. Refer to individual Series

2016-04-01 | E-GEOD-77771 | biostudies-arrayexpress

BRD9 is a regulator of androgen receptor signaling and prostate cancer progression - ChIP-Seq

Project description:BRD9 is a regulator of androgen receptor signaling and prostate cancer progression - ChIP-Seq

| PRJNA611536 | ENA

The miR-96 and RARG signaling axis governs androgen signaling and prostate cancer progression

Project description:This SuperSeries is composed of the SubSeries listed below.